查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750864

Humira市场规模、份额、趋势分析报告：按产品、应用、分销管道、地区、细分市场预测，2025 年至 2030 年

Humira Market Size, Share & Trends Analysis Report By Product (Branded, Biosimilar), By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

Humira市场成长与趋势

根据Grand View Research, Inc.的最新报告，预计到2030年全球Humira市场规模将达到41.1亿美元，预测期内复合年增长率为-11.29%。

儘管下滑，但受全球类风湿性关节炎、克隆氏症和溃疡性大肠炎等自体免疫疾病盛行率上升的推动，市场需求持续成长。多年来，Humira一直是这些疾病治疗的基石，对有效生物製药的需求仍然强劲。然而，随着市场动态的变化，生物相似药的进入和法律规范也在不断演变。

Humira)市场占有率的下降主要归因于生物相似药的日益普及。随着关键专利到期，以及监管支持和成本控制策略的推动，生物相似药的供应日益充足，尤其是在新兴市场。这促使人们转向更廉价的替代品，从而增加了生物相似药的采用率，并扩大了患者的可及性。虽然Humira的疗效已得到证实，并且仍然是治疗自体免疫疾病的首选药物，但生物相似药的日益普及导致价格竞争加剧，削弱了其整体市场主导地位。

儘管市场萎缩，但仍存在巨大的成长机会，尤其是在医疗基础设施发达、自体免疫疾病认知度不断提升的新兴市场。 Humira适应症的扩大以及无柠檬酸盐和高浓度注射剂等新剂型的推出，正在推动Humira的持续需求，尤其是在医疗框架和报销支持更强的地区。

包括艾伯维、安进、山德士和梯瓦等主要生物相似药製造商在内的製药公司，正透过策略联盟、产品差异化和生命週期管理来应对不断变化的市场格局。儘管生物相似药将于2024年问世，但艾伯维凭藉其品牌忠诚度、丰富的临床数据和医生的信任，仍保持着较高的市场占有率。

Simlandi 等可互换生物相似药的上市，以及 Evernorth 零自付费用计划等近期进展，凸显了人们对平价医疗服务日益增长的需求。随着生物相似药快速核准并持续扩大市场份额，Humira)产业的竞争格局也日益活跃。预计Humira市场将继续发展，主要企业将专注于扩大适应症、改善给药系统，并渗透到尚未开发的地区，以跟上自体免疫疾病治疗领域不断变化的动态。

Humira市场报告重点

  • 在产品层面，原创品牌产品将占据市场主导地位，到2024年将达到87.0%的份额。这种主导地位归因于经过验证的临床疗效、在多种自体免疫疾病方面的广泛监管核准以及医生和患者对该品牌的长期信任。
  • 根据应用，类风湿性关节炎将占据市场主导地位，到 2024 年将占 20.5% 的份额。
  • 根据分销管道，医院药房将引领市场，到 2024 年将占据 41.0% 的份额。对于需要专门治疗的患者， Humira是透过医院开立和配发的首选治疗方案。
  • 市场主要企业包括艾伯维、安进、勃林格殷格翰、辉瑞、三星Bioepis、山德士等。竞争愈演愈烈，尤其是随着Humira关键专利到期，市场向广泛的Adalimumab单抗治疗方法开放，生物相似药製造商的影响力不断扩大。
  • 2024年6月，Coherus BioSciences揭露已完成将修美乐（Humira）的生物相似药YUSIMRY以4,000万美元现金出售给香港健友实业有限公司，该交易于2024年6月26日完成交割。 YUSIMRY将继续由香港健友实业的子公司美泰製药（Meitheal Pharmaceuticals）在美国进行商业化。 Coherus表示，此次资产剥离符合公司加强肿瘤产品组合的策略重点。

目录

第一章调查方法与范围

第二章执行摘要

第三章Humira市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章Humira市场：依产品、业务分析

  • 2024 年及 2030 年产品市场占有率
  • 产品细分仪表板
  • 市场规模、预测与趋势分析（按产品，2018-2030 年）
  • 原厂产品
  • 生物相似药

第五章Humira市场：按应用、业务分析

  • 2024 年和 2030 年应用市场占有率
  • 应用程式细分仪表板
  • 市场规模、预测与趋势分析（按应用，2018-2030 年）
  • 类风湿性关节炎
  • 干癣性关节炎
  • 克隆氏症
  • 溃疡性大肠炎
  • 僵直性脊椎炎
  • 其他的

第六章Humira市场：依分销管道、业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 网路药局

第七章Humira市场：区域、估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • AbbVie
    • Alvotech
    • Amgen Inc.
    • Boehringer Ingelheim Pharmaceuticals Inc.
    • Celltrion Inc.
    • Coherus Biosciences公司
    • Fresenius Kabi AG
    • 富士软片协和基兰生物製剂株式会社
    • Pfizer Inc.
    • Samsung Bioepis
    • Sandoz Inc.
Product Code: GVR-4-68040-570-9

Humira Market Growth & Trends:

The global humira market size is projected to reach USD 4.11 billion by 2030, declining at a CAGR of -11.29% during the forecast period, according to a new report by Grand View Research, Inc. Despite this decline, the market continues to experience sustained demand, driven by the rising global prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Humira has long been a cornerstone of treatment for these conditions, and demand for effective biologic therapies remains strong. However, as the market shifts, the entry of biosimilars and evolving regulatory frameworks are reshaping its dynamics.

The decline in Humira's market share is largely attributed to the growing availability of biosimilars. With the expiration of key patents, biosimilars, driven by regulatory support and cost-containment strategies, are becoming increasingly accessible, particularly in emerging markets. As a result, there is a shift towards more affordable alternatives, increasing the adoption of biosimilars and expanding patient access. Although Humira's proven efficacy continues to make it a top choice for managing autoimmune diseases, the increasing presence of biosimilars leads to a competitive pricing environment and reduces its overall market dominance.

Despite the market's decline, significant growth opportunities remain, especially in developing regions where healthcare infrastructure is improving and awareness of autoimmune conditions is rising. The expanding indications for Humira and new formulations, such as citrate-free versions and high-concentration injectables, drive continued demand for the drug, particularly in regions with a strong healthcare framework and reimbursement support.

Pharmaceutical companies, including AbbVie and leading biosimilar manufacturers like Amgen, Sandoz, and Teva, are navigating the evolving landscape through strategic partnerships, product differentiation, and lifecycle management. AbbVie has retained significant market share through brand loyalty, extensive clinical data, and physician trust, despite the emergence of biosimilars in 2024.

Recent developments, such as the launch of interchangeable biosimilars like Simlandi and initiatives like Evernorth's zero out-of-pocket cost program, highlight the growing push for affordable access. As biosimilars rapidly gain approval and expand market presence, the competitive landscape of the Humira industry is becoming increasingly dynamic. The market is expected to continue evolving, with key players focusing on expanding indications, enhancing delivery systems, and penetrating underserved regions to capitalize on the shifting dynamics of autoimmune disease treatment.

Humira Market Report Highlights:

  • Based on product, Branded Humira dominated the market, accounting for 87.0% of the share in 2024. This dominance is attributed to its proven clinical efficacy, wide-ranging regulatory approvals across multiple autoimmune conditions, and long-standing physician and patient trust in the brand.
  • Based on application, rheumatoid arthritis dominated the market and accounted for a share of 20.5% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
  • Based on distribution channel, hospital Pharmacies led the market and accounted for a share of 41.0% in 2024, driven by the growing demand for biologic therapies used in managing autoimmune conditions. Humira is a preferred treatment option prescribed and dispensed through hospital settings for patients requiring specialized care.
  • Key players in the market include AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Samsung Bioepis, and Sandoz. Competition is intensifying with the growing presence of biosimilar manufacturers, especially following the expiration of Humira's key patents, which has opened the market to a broader range of adalimumab-based therapies.
  • In June 2024, Coherus BioSciences revealed it had completed the sale of its Humira biosimilar, YUSIMRY, to Hong Kong King-Friend Industrial Co. Ltd. for USD 40 million in cash, with the transaction closing on June 26, 2024. YUSIMRY will continue to be commercialized in the U.S. by Meitheal Pharmaceuticals, a subsidiary of HKF. Coherus noted that the divestiture aligns with its strategic focus on advancing its oncology portfolio.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Humira Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Humira Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.5. Biosimilar
    • 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Humira Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Rheumatoid Arthritis
    • 5.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 5.5. Psoriatic Arthritis
    • 5.5.1. Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
  • 5.6. Crohn's Disease
    • 5.6.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
  • 5.7. Ulcerative Colitis
    • 5.7.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
  • 5.8. Ankylosing Spondylitis
    • 5.8.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Humira Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Humira Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Humira Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Humira Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Humira Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AbbVie
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Alvotech
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Amgen Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Celltrion Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Coherus Biosciences, Inc
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Fresenius Kabi AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Fujiflim Kyowa Kiran Biologics Co., Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Pfizer Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Samsung Bioepis
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Sandoz Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Humira market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global Humira market, by product, 2018 - 2030 (USD Million)
  • Table 5. Global Humira market, by application, 2018 - 2030 (USD Million)
  • Table 6. Global Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America Humira market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America Humira market, by product, 2018 - 2030 (USD Million)
  • Table 9. North America Humira market, by application, 2018 - 2030 (USD Million)
  • Table 10. North America Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. Humira market, by product, 2018 - 2030 (USD Million)
  • Table 12. U.S. Humira market, by application, 2018 - 2030 (USD Million)
  • Table 13. U.S. Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14. Canada Humira market, by product, 2018 - 2030 (USD Million)
  • Table 15. Canada Humira market, by application, 2018 - 2030 (USD Million)
  • Table 16. Canada Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico Humira market, by product, 2018 - 2030 (USD Million)
  • Table 18. Mexico Humira market, by application, 2018 - 2030 (USD Million)
  • Table 19. Mexico Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Europe Humira market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe Humira market, by product, 2018 - 2030 (USD Million)
  • Table 22. Europe Humira market, by application, 2018 - 2030 (USD Million)
  • Table 23. Europe Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. UK Humira market, by product, 2018 - 2030 (USD Million)
  • Table 25. UK Humira market, by application, 2018 - 2030 (USD Million)
  • Table 26. UK Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27. Germany Humira market, by product, 2018 - 2030 (USD Million)
  • Table 28. Germany Humira market, by application, 2018 - 2030 (USD Million)
  • Table 29. Germany Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. France Humira market, by product, 2018 - 2030 (USD Million)
  • Table 31. France Humira market, by application, 2018 - 2030 (USD Million)
  • Table 32. France Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy Humira market, by product, 2018 - 2030 (USD Million)
  • Table 34. Italy Humira market, by application, 2018 - 2030 (USD Million)
  • Table 35. Italy Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36. Spain Humira market, by product, 2018 - 2030 (USD Million)
  • Table 37. Spain Humira market, by application, 2018 - 2030 (USD Million)
  • Table 38. Spain Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. Norway Humira market, by product, 2018 - 2030 (USD Million)
  • Table 40. Norway Humira market, by application, 2018 - 2030 (USD Million)
  • Table 41. Norway Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark Humira market, by product, 2018 - 2030 (USD Million)
  • Table 43. Denmark Humira market, by application, 2018 - 2030 (USD Million)
  • Table 44. Denmark Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden Humira market, by product, 2018 - 2030 (USD Million)
  • Table 46. Sweden Humira market, by application, 2018 - 2030 (USD Million)
  • Table 47. Sweden Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Humira market, by country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific Humira market, by product, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific Humira market, by application, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52. Japan Humira market, by product, 2018 - 2030 (USD Million)
  • Table 53. Japan Humira market, by application, 2018 - 2030 (USD Million)
  • Table 54. Japan Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55. China Humira market, by product, 2018 - 2030 (USD Million)
  • Table 56. China Humira market, by application, 2018 - 2030 (USD Million)
  • Table 57. China Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. India Humira market, by product, 2018 - 2030 (USD Million)
  • Table 59. India Humira market, by application, 2018 - 2030 (USD Million)
  • Table 60. India Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Australia Humira market, by product, 2018 - 2030 (USD Million)
  • Table 62. Australia Humira market, by application, 2018 - 2030 (USD Million)
  • Table 63. Australia Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea Humira market, by product, 2018 - 2030 (USD Million)
  • Table 65. South Korea Humira market, by application, 2018 - 2030 (USD Million)
  • Table 66. South Korea Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand Humira market, by product, 2018 - 2030 (USD Million)
  • Table 68. Thailand Humira market, by application, 2018 - 2030 (USD Million)
  • Table 69. Thailand Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America Humira market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America Humira market, by product, 2018 - 2030 (USD Million)
  • Table 72. Latin America Humira market, by application, 2018 - 2030 (USD Million)
  • Table 73. Latin America Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil Humira market, by product, 2018 - 2030 (USD Million)
  • Table 75. Brazil Humira market, by application, 2018 - 2030 (USD Million)
  • Table 76. Brazil Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina Humira market, by product, 2018 - 2030 (USD Million)
  • Table 78. Argentina Humira market, by application, 2018 - 2030 (USD Million)
  • Table 79. Argentina Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Humira market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa Humira market, by product, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa Humira market, by application, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa Humira market, by product, 2018 - 2030 (USD Million)
  • Table 85. South Africa Humira market, by application, 2018 - 2030 (USD Million)
  • Table 86. South Africa Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia Humira market, by product, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia Humira market, by application, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. UAE Humira market, by product, 2018 - 2030 (USD Million)
  • Table 91. UAE Humira market, by application, 2018 - 2030 (USD Million)
  • Table 92. UAE Humira market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait Humira market, by product, 2018 - 2030 (USD Million)
  • Table 94. Kuwait Humira market, by application, 2018 - 2030 (USD Million)
  • Table 95. Kuwait Humira market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Humira market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Humira market dynamics
  • Fig. 12 Humira market: Porter's five forces analysis
  • Fig. 13 Humira market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Branded market, 2018 - 2030 (USD Million)
  • Fig. 16 Biosimilar market, 2018 - 2030 (USD Million)
  • Fig. 17 Application market, 2018 - 2030 (USD Million)
  • Fig. 18 Rheumatoid Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 19 Psoriatic Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 20 Crohn's Diseases market, 2018 - 2030 (USD Million)
  • Fig. 21 Ulcerative Colitis market, 2018 - 2030 (USD Million)
  • Fig. 22 Ankylosing Spondylitis market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 25 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 26 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 27 Online Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Humira market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America Humira market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. Humira market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada Humira market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico Humira market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Humira market, 2018 - 2030 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK Humira market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany Humira market, 2018 - 2030 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France Humira market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy Humira market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain Humira market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway Humira market, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden Humira market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark Humira market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific Humira market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Humira market, 2018 - 2030 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Humira market, 2018 - 2030 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India Humira market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia Humira market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea Humira market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand Humira market, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America Humira market, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil Humira market, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina Humira market, 2018 - 2030 (USD Million)
  • Fig. 73 MEA Humira market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa Humira market, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia Humira market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE Humira market, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait Humira market, 2018 - 2030 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework